The Kezar Life Sciences covalent immunoproteasome inhibitor, KZR-616 , licensed from Onyx , targets the LMP7 and LMP2 active sites of the immunoproteasome, and is currently in Ph. II trials for autoimmune disorders (30 mg SC QW for 2 weeks, then 45 mg SC weekly for 14 weeks). More subunit-selective, proteasome-sparing reversible-covalent LMP7 [...]
< 1 minute read
Dec. 16, 2021
KZR-616: a Covalent Immunoproteasome Inhibitor
KZR-616
covalent immunoproteasome inhibitor subcutaneous agent in Ph. I/II for SLE and LN designed from proteasome inhibitors Drug Metabolism and Disposition Kezar Life Sciences, San Francisco, US
Loading...
